Loss of O6-Methylguanine-DNA Methyltransferase Protein Expression Is a Favorable Prognostic Marker in Diffuse Large B-Cell Lymphoma

Although aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase (MGMT) is a favorable prognostic marker in patients with diffuse large B-cell lymphoma (DLBCL), MGMT protein expression has not been thoroughly examined. The aim of this study was to evaluate the clinical implication of MGMT protein expression and its correlation with promoter hypermethylation of the gene. We investigated MGMT protein expression by immunohistochemical analysis of 63 DLBCL patients who received cyclophosphamide as part of multidrug regimens. In addition, promoter methylation of the MGMT gene was analyzed by a methylation-specific polymerase chain reaction assay, and correlations with chemotherapeutic effect and prognosis were statistically evaluated. Immunohistochemical assay results for MGMT protein were negative in 30.2% of patients with newly diagnosed DLBCL. Immunostaining results were closely correlated with the methylation status of the promoter. Promoter DNA methylation of the gene was not detected in 34 (81.0%) of 42 tumor samples determined to be MGMT-positive DLBCL by immunostaining and was detected in 15 (88.2%) of 17 cases of MGMT-negative DLBCL. Overall survival (OS) and disease-free survival (DFS) rates were significantly higher in MGMT-negative patients than in MGMT-positive patients (5-year OS, 81.3% versus 56.6% [P = .0375]; 5-year DFS, 66.3% versus 39.9% [P = .0121]). The combined rate for complete response (CR) plus unconfirmed CR was significantly higher in MGMT-negative patients (15/19, 79.0%) than in MGMT-positive patients (25/44, 56.8%) (P = .0488). A multivariate analysis showed that absence of MGMT expression was an independent prognostic factor for OS (relative risk, 4.09; P = .0258). Lack of MGMT protein expression is associated with aberrant promoter DNA methylation and appears to be a useful marker for predicting the survival of DLBCL patients.

[1]  T. Miyazaki,et al.  Long-term Results of a Multicenter Randomized, Comparative Trial of Modified CHOP versus THP-COP versus THP-COPE Regimens in Elderly Patients with Non-Hodgkin’s Lymphoma , 2005, International journal of hematology.

[2]  T. Kinoshita.  Epigenetic Inactivation of Tumor Suppressor Genes in Hematologic Malignancies , 2004, International journal of hematology.

[3]  D. Xie,et al.  DNA repair gene O6‐methylguanine‐DNA methyltransferase: Promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors , 2003, Molecular carcinogenesis.

[4]  M. Hashimoto,et al.  Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias , 2002, The Journal of pathology.

[5]  J. A. Castillejo,et al.  5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. , 2002, Blood.

[6]  S. Goodman,et al.  Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. , 2002, Journal of the National Cancer Institute.

[7]  D. Sidransky,et al.  O6-Methylguanine-DNA Methyltransferase Promoter Hypermethylation Shifts the p53 Mutational Spectrum in Non-Small Cell Lung Cancer , 2001 .

[8]  Y. Yonekawa,et al.  Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene. , 2001, Carcinogenesis.

[9]  A. Sánchez-Aguilera,et al.  Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. , 2001, The American journal of pathology.

[10]  J. Herman,et al.  Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. , 2001, Cancer research.

[11]  H. G. Einsiedel,et al.  Prognostic value of p16INK4a gene deletions in pediatric acute lymphoblastic leukemia , 2001 .

[12]  M. Toyota,et al.  Methylation profiling in acute myeloid leukemia. , 2001, Blood.

[13]  J. Román,et al.  Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome , 2001, British journal of haematology.

[14]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[15]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. , 2000, Cancer research.

[16]  I. Wong,et al.  Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.

[17]  C. Bartram,et al.  Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. , 1999, Blood.

[18]  J. Herman,et al.  Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. , 1999, Blood.

[19]  M. Berger,et al.  O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[21]  P. Goodfellow,et al.  A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers , 1999, Molecular carcinogenesis.

[22]  T. Brent,et al.  Methylation of selected CpGs in the human O6‐methylguanine‐DNA methyltransferase promoter region as a marker of gene silencing , 1999, Molecular carcinogenesis.

[23]  H. Eyre,et al.  Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Volm,et al.  O6‐methylguanine‐DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts , 1998, International journal of cancer.

[25]  M. Berger,et al.  O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. , 1998, Cancer research.

[26]  J. Costello,et al.  Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene , 1997, Molecular and cellular biology.

[27]  T. Brent,et al.  Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. , 1997, Cancer research.

[28]  T. Kinoshita,et al.  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. , 1997, Blood.

[29]  P. Burton,et al.  Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. , 1997, Blood.

[30]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Prados,et al.  Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. , 1996, Cancer research.

[32]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[33]  M. Berger,et al.  Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. , 1993, Cancer research.

[34]  T. Byers,et al.  Repair of DNA containing O6‐alkylguanine , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[37]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[38]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.

[39]  M. Dolan,et al.  Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. , 1995, Progress in nucleic acid research and molecular biology.

[40]  T. Brent,et al.  Immunoaffinity purification of human O6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies. , 1990, Cancer research.